Agilent Technologies Announces Major NMR/MRI Sale to Adam Mickiewicz University in Poland
Product News Jun 23, 2011
Agilent Technologies Inc. has announced a $6 million sale of nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging (MRI) systems in collaboration with the Adam Mickiewicz University in Poznan, Poland.
The instruments will form the core of the new NanoBioMedical Centre, a multidisciplinary unit supporting master’s and doctoral research programs in nanoscience and nanotechnology.
The multi-system sale includes several NMR systems at 400 MHz, 600 MHz and 800 MHz. In addition, the center will be acquiring an Agilent 9.4 Tesla MRI system.
Each of these systems will be equipped with the new Direct Drive 2 console, configured as a single platform to support a broad suite of applications for both NMR and MRI.
The 9.4 Tesla ultra-high field MRI magnet enables greater resolution and sensitivity for the in vivo visualization of biological structures and processes.
“Agilent systems are known for their ease of use, reliability and flexibility,” said Professor Stefan Jurgen, director of the NanoBioMedical Centre. “We look forward to using these tools to advance our research and train the next generation of nanoscientists.”
“Agilent has a long tradition of supporting academic research efforts, and this collaboration is a major win for our expansion of cutting-edge magnetic resonance systems in Europe,” said Frederic Laget, vice president, Life Sciences Group EMEAI, Agilent Technologies.
Agilent’s portfolio of NMR and MRI instrumentation and technology includes:
• The Direct Drive 2 NMR/MRI console that offers improved electronics performance to increase speed, amplitude and resolution.
• Broad NMR probe selection, including the high-performance OneNMRProbe at 400, 500 and 600 MHz that can be automatically tuned with the ProTune PZT module.
• A broad portfolio of MRI systems ranging from field strengths of 4.7 Tesla to 16.4 Tesla providing the most powerful and stable fields in which to image.